Amylin Pharmaceuticals, the maker of the diabetes drugs Bydureon and Byetta, is seeking a buyer after rejecting an unsolicited bid from big pharma Bristol-Myers Squibb, two people with knowledge of the matter said.
Amylin has hired Credit Suisse Group AG and Goldman Sachs Group Inc. to help solicit possible offers, said one of the people, who asked not to be identified because the talks are private.
A number of drugmakers are considering whether to acquire San Diego-based Amylin to gain access to its diabetes franchise, according to another person familiar with the talks. Amylin began reaching out to potential buyers last week, one of the people said.
Read the full story at Bloomberg (link no longer available)
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news - latest deal news for top 50 pharma / big pharma companies
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity